<DOC>
	<DOC>NCT02801370</DOC>
	<brief_summary>This is a prospective, randomized, double-blind, sham-controlled, multicenter, Phase 3 study in which eligible subjects with acute otitis externa (AOE) will be randomized to receive a single administration of either 12 mg OTO-201 or Sham-Control (empty syringe) to the external auditory canal of the affected ear(s).</brief_summary>
	<brief_title>Phase 3 Study of OTO-201 in Acute Otitis Externa</brief_title>
	<detailed_description />
	<mesh_term>Otitis</mesh_term>
	<mesh_term>Otitis Externa</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<criteria>Inclusion Criteria includes, but is not limited to: Subject is a male or female age 6 months or older Subject has a clinical diagnosis of unilateral or bilateral acute otitis externa Subject or subject's caregiver is willing to comply with the protocol and attend all study visits Exclusion Criteria includes, but is not limited to: Subject has tympanic membrane perforation Subject has eczematoid otitis externa Subject has diabetes mellitus</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>